PMA device
iStent Trabecular Micro-Bypass Stent System, iStent inject Trabecular Micro-Bypass System, iStent inject W Trabecular Mi
Glaukos Corporation · Intraocular Pressure Lowering Implant (OGO, Class III) · First FDA decision Dec 16, 2014, newest Aug 29, 2022Glaucoma
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
9
PMA pathway
Device trials
33
Naming "iStent Trabecular Micro-Bypass"
MAUDE reports
530
Brand "iStent Trabecular Micro-Bypass", since 2015
PubMed studies
41
Mentioning "iStent Trabecular Micro-Bypass"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing iStent Trabecular Micro-Bypass Stent System, iStent inject Trabecular Micro-Bypass System, iStent inject W Trabecular Mi
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 9 decisions filed under this name.
- iStent Trabecular Micro-Bypass Stent System, iStent inject Trabecular Micro-Bypass System, iStent inject W Trabecular MiPMA supplement
P170043-S014 · Decided Aug 29, 2022 · 90 days after receipt · Normal 180 Day Track
Device type: Intraocular pressure lowering implant (OGO) · Ophthalmology
- iStent Trabecular Micro-Bypass Stent System, iStent inject Trabecular Micro-Bypass System, iStent inject W Trabecular MiPMA supplement
P080030-S024 · Decided Aug 29, 2022 · 90 days after receipt · Normal 180 Day Track
Device type: Intraocular pressure lowering implant (OGO) · Ophthalmology
- iStent Trabecular Micro-Bypass Stent SystemPMA supplement
P080030-S021 · Decided May 29, 2018 · 89 days after receipt · Normal 180 Day Track
Device type: Intraocular pressure lowering implant (OGO) · Ophthalmology
3 more FDA decisions with a free account
Older decisions: P080030-S016, P080030-S013, P080030-S012
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational determinationOn the books20.36Updated Oct 6, 2026
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational analysisReview closedCAG-00466NUpdated Sep 18, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "iStent Trabecular Micro-Bypass", any status and sponsor, newest update first.
- Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle GlaucomaRecruiting
Jonathon MyersAcademic, hospital or other
NCT07228221 · 20 participants (planned) · Start Jan 5, 2026 · Primary completion Aug 30, 2031
Device: iStent infinite trabecular micro-bypass system model iS3 · For: Open Angle Glaucoma; Pigmentary Glaucoma; Pseudoexfoliation Glaucoma
Sites: Philadelphia, Pennsylvania
Sight Sciences, Inc.Not on our public-company list
NCT04658095 · 10 participants · Start Jan 11, 2022 · Primary completion Nov 18, 2022
Device: Canaloplasty and trabeculotomy with the OMNI system.; iStent inject and 1 more · For: Glaucoma, Open-Angle
Sites: Frankfurt, Germany; Barcelona, Spain; Valencia, Spain · 5 sites in all
Yu-Ting TsaoAcademic, hospital or other
NCT06630546 · 71 participants · Start May 16, 2022 · Primary completion Apr 30, 2023
Device: first generation iStent (Glaukos, San Clemente, CA, USA) insertion; phacoemulsification · For: Primary Open Angle Glaucoma (POAG); Istent Inject W; Normal Tension Glaucoma (NTG)
Sites: Taoyuan City, Taiwan
30 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "iStent Trabecular Micro-Bypass", and for the whole product code for context.
This brand
530 reports: 101 malfunction, 429 injury, 0 death
Whole product code OGO
2,634 reports: 667 malfunction, 1,967 injury, 0 death
Newest reports for this brand
2032546-2026-00082 · Received Sep 4, 2026 · Event dated Aug 25, 2026
Device type: Intraocular Pressure Lowering Implant (OGO)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Uveitis
2032546-2026-00079 · Received Sep 1, 2026 · Event dated Aug 19, 2026
Device type: Intraocular Pressure Lowering Implant (OGO)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Intraocular Pressure Increased
2032546-2026-00055 · Received Jun 4, 2026 · Event dated May 14, 2026
Device type: Intraocular Pressure Lowering Implant (OGO)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Intraocular Pressure Increased
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "iStent Trabecular Micro-Bypass"[tiab]. The summary above synthesizes these.
- Standalone iStent Trabecular Micro-bypass Glaucoma Surgery: A Systematic Review and Meta-Analysis.
Healey PR, Clement CI, Kerr NM, et al. · J Glaucoma · 2021Meta-Analysis, Systematic Review
- iStent trabecular micro-bypass stent for open-angle glaucoma.
Le K, Saheb H · Clin Ophthalmol · 2014Review
- Glaukos iStent Trabecular Micro-Bypass.
Nichamin LD · Middle East Afr J Ophthalmol · 2009
- iStent Trabecular Micro-bypass Stent Implantation Combined with Phacoemulsification for Open-Angle Glaucoma: A 2-Year Post-marketing Surveillance Study in Japan.
Inatani M, Kohama I, Chu A · Adv Ther · 2022Observational Study, Research Support, Non-U.S. Gov't
- [Not Available].
Choo DM, Durham TA, Zhang H, et al. · Graefes Arch Clin Exp Ophthalmol · 2026Comparative Study, English Abstract
- Outcomes of Combined iStent Trabecular Micro-Bypass and Cataract Surgery for the Treatment of Open-Angle Glaucoma in a Saudi Population.
Al Habash A, Khan O · Clin Ophthalmol · 2020
- iStent Trabecular Micro-Bypass Stent Implantation with Cataract Surgery in a Japanese Glaucoma Population.
Nitta K, Yamada Y, Morokado S, et al. · Clin Ophthalmol · 2020
- The iStent trabecular micro-bypass stent: a case series.
Vandewalle E, Zeyen T, Stalmans I · Bull Soc Belge Ophtalmol · 2009Evaluation Study
- Fellow-Eye Comparison between Phaco-Microhook Ab-Interno Trabeculotomy and Phaco-iStent Trabecular Micro-Bypass Stent.
Takayanagi Y, Ichioka S, Ishida A, et al. · J Clin Med · 2021
- Cost-effectiveness analysis of iStent trabecular micro-bypass stent for patients with open-angle glaucoma in Colombia.
Ordóñez JE, Ordóñez A, Osorio UM · Curr Med Res Opin · 2019Comparative Study, Research Support, Non-U.S. Gov't
- A review of the iStent(®) trabecular micro-bypass stent: safety and efficacy.
Wellik SR, Dale EA · Clin Ophthalmol · 2015Review
- Mid-term evaluation of the safety and efficacy of the iStent trabecular micro-bypass system combined with phacoemulsification.
Kozera M, Konopiska J, Rwkas M · Adv Clin Exp Med · 2021
Other devices of this type
Also filed under product code OGO.
- iStent inject Trabecular MicroBypass SystemGlaukos Corporation · PMA 2025
- Hydrus MicrostentAlcon Research, LLC · PMA 2025
- iStent inject® W Trabecular Micro-Bypass System Model iS2Glaukos Corporation · PMA 2025
- CyPass System 241-SAlcon Research, Ltd. · PMA 2018
- Glaukos Trabecular Micro Bypass Stent Model GTS100R/LGlaukos Corporation · PMA 2013
- CyPass Micro-StentAlcon Research, Ltd. · PMA 2020
- iStent® Trabecular Mjcro-Bypass Stent System, Model GTS100Glaukos Corporation · PMA 2024
- Hydrus MicrosentAlcon Research, LLC · PMA 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.